![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.75 | 1.70 | 1.80 | 1.75 | 1.75 | 1.75 | 250,114 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.34 | 13.57M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2019 15:28 | Yes, only 117m shares market cap really is peanuts if they get approval, ok I'm bias but 90% confident, simply because excellent product and its not life threatening, I think but I'm not as doctor. But the benefits are massive to a patient. Surely FDA will say YES. | ![]() montyhedge | |
22/5/2019 15:07 | Hey Monty, presumably you have been in for a while? Onwards & upwards | ![]() ny boy | |
22/5/2019 14:47 | I'm 90% confident of approval its not a life threatening drug has I understand, so FDA giving it the nod seems nailed on to me, for the benefit its gives patients. I see the share price doubling coming months after 27th if given the ok, as deals get signed. Lets hopefully enjoy the ride. | ![]() montyhedge | |
22/5/2019 14:43 | More buying, gobbling up a few sellers | ![]() ny boy | |
22/5/2019 12:52 | Listening to that podcast with the CEO, the only risk, which seems reduced, is we don’t want a CRL from the FDA, it’s not as bad as rejection but it would cause the share price to obviously drop, which if it happened, might be viewed as a buying opportunity but depends on what the CRL contents are. Still I am 75% confident of approval but everyone has to dyor The U.S. Food and Drug Administration (FDA) sends a complete response letter (CRL) to communicate it has completed its review of a new or generic drug application, and it decided that it will not approve it for marketing in its present form. Receiving one of these letters from the FDA is never good news, but their long-term impact varies. I reckon around 150p up to 27 July but with heightened volatility the week before, certainly exciting few months! So far, there seems very little reason to sell, as there is still lots of buying interest, every mini pull back, has been bought! | ![]() ny boy | |
22/5/2019 12:47 | Does anyone know of an example of a drug where FDA has been rejected following EU approval? | ![]() 78steve | |
22/5/2019 12:39 | No ......77.5% ...now that's fair | ![]() kop202 | |
22/5/2019 11:16 | I think 80% is fair. But unlike my last bet on immu this has still has value if fda say no. I would see the negative outcome as being a request for more date + fast track approval. But not too sure what the share price would do in that case. I see significant gains before July here anyway IMO. | jimbob49 | |
22/5/2019 11:07 | Let’s say 75%! Looking good though! 👌🤞 | ![]() ny boy | |
22/5/2019 10:53 | I dont want to be too optimistic however with the director buys and the way this is moving i feel it is almost 100% certain that we will get approval on the 27th of July | sharestobuy | |
22/5/2019 10:46 | Thank you - a good listen. | ![]() 2theduke | |
22/5/2019 09:43 | Podcast interview with CEO, discusses FDA from ~9 mins | ![]() paleje | |
22/5/2019 09:36 | I loaded up at 100p area. Lets see if we can close above 115p, if there is a pull back I will add more but I don’t need anymore at this juncture. I suspect there will be plenty of buying interest if there is a pull back, as many missed earlier pull backs! GLA | ![]() ny boy | |
22/5/2019 08:39 | Ok so I bought a few more this morning. I thought 115p was going to be a barrier but certainly no sign of any selling at this level. Onwards and upwards... | ![]() nobbygnome | |
22/5/2019 08:22 | Morning STX’ers, Trying to break 115p, buying resumes | ![]() ny boy | |
21/5/2019 18:40 | Topped up at £1.15. Hoping for £3 or more by end of July | sharestobuy | |
21/5/2019 16:32 | Onwards and upwards, not sure if we can break 115p today but it’s coming, no reason to sell imo Market closed but note a big volume day! | ![]() ny boy | |
21/5/2019 15:12 | Widening the spread to try and flush out a few weak holders at 115 resistance, buyers to counter any sells. Hold patiently is the best policy imo MM putting through a lot of misleading trades, some buys showing as sells, duplicate trades, wider spreads etc | ![]() ny boy | |
21/5/2019 14:32 | They keep mugging a few each decade since 20p’s, some bought back and saw the opportunity, some are kicking themselves, even today a few big sells got mugged, basically why sell, unless you need the money! Just buy & hold imo This will really start motoring above 115p resistance. | ![]() ny boy | |
21/5/2019 14:25 | That shake didn't last long now back up higher on day | ![]() 78steve | |
21/5/2019 14:24 | Solely from a momentum up to the FDA readout we have similarities to IMM but in the case here if we fail with FDA or get a very limited label which is In my opinion possible we are not going from 170 to 30p on the day. We will have to spend more cash and time but with the new data already at hand we will get the extended label eventually I see continued rise up to say mid July then some sort of pullback ahead of results that is the usual pattern in these circumstances. If we were to get FDA full label we may see a bidding battle which could lead to s takeout somewhere between £5/£7 depending on the interested parties and that could even be slightly conservative. | ![]() best1467 | |
21/5/2019 14:19 | There we go.....as predicted. How low will they take it? | ![]() nobbygnome | |
21/5/2019 13:22 | To get back to STX, I am expecting a MM inspired tree shake in the not too distant future. If it happens, I will use the opportunity to get a few more.... | ![]() nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions